跳至主要内容
临床试验/NCT02404792
NCT02404792已完成不适用

Exercise for Healthy Aging: The Impact of HIV and Aging on Physical Function and the Somatopause

University of Colorado, Denver1 个研究点 分布在 1 个国家目标入组 69 人开始时间: 2015年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
69
试验地点
1
主要终点
Time to Rise From a Chair 10 Times (Modified From the Original Short Physical Performance Battery)

研究概览

简要总结

The primary objective of this proposal is to compare a moderate or high intensity exercise intervention to improve physical function in persons aging with Human Immunodeficiency Virus (HIV).

详细描述

The primary objective of this proposal is to compare a moderate or high intensity exercise intervention to improve physical function in persons aging with HIV. Both HIV-infected and HIV-uninfected older adults will be assigned to a moderate intensity cardiovascular and resistance training intervention for 12 weeks, and then randomized to either continue moderate intensity exercise, or increase to high intensity exercise for an additional 12 weeks. The primary outcome is the impact of exercise on physical function, as measured by the overall score of a modified Short Physical Performance Battery (mSPPB) and the chair rise time from the mSPPB. The secondary outcomes include changes in insulin-like growth factor-1 (systemic and local) and inflammation (interleukin-6 (IL-6), soluble tumor necrosis factor receptors 1 and 2 (sTNFR-1 and sTNFR-2)).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
50 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Ages 50-75
  • •HIV+ must be on ART for a minimum of 2 years with viral load <200 copies/mL
  • •Sedentary
  • •cluster of differentiation 4 (CD4) T-cell count >200 cells/microliter
  • •BMI >19 and <41
  • •Among females, must be post-menopausal
  • •Able to perform activities of daily living with out assistance

排除标准

  • •Diabetes, poorly controlled with HgbA1c >7.5; on insulin
  • •On growth hormone (or growth hormone axis) therapy, intramuscular testosterone, corticosteroids.
  • •Known active hepatitis B or C (viremia).
  • •Severe liver disease
  • •Uncontrolled hypertension (SPB >180 or diastolic >100).
  • •Underlying cardiac conditions that would make exercise or exercise testing potentially unsafe (unstable ischemic heart disease, Class III or IV heart failure clinically significant aortic stenosis, uncontrolled angina, or uncontrolled arrhythmia)
  • •pulmonary disease requiring the use of supplemental oxygen ≥ 4 liters with physical exertion
  • •current diagnosis of malignancy (excluding non-melanoma skin cancers) within 48 weeks prior to enrollment
  • •surgery/trauma/injury/fracture within 24 weeks prior to enrollment that may impact a subject's ability to exercise
  • •history of stroke with residual deficits that may impact ability to exercise; orthopedic problems (e.g., severe osteoarthritis, rheumatoid arthritis) that greatly limit the ability to perform moderate-intensity resistance exercise (e.g., unable to be properly positioned in exercise equipment or to have severely restricted range of motion even after modifications have been made)
  • •weight over 300 pounds
  • •Montreal Cognitive Assessment (MOCA) score < 18 (will be evaluated at screening visit after consent obtained)
  • •AIDS-defining opportunistic infection within the 24 weeks prior to enrollment
  • •Person who appear to have unstable health, are incapable of safely participating in the exercise intervention, or are felt to have a life expectancy of < 1 year.
  • •Participants on anticoagulants (clopidogrel, Coumadin, etc) will be excluded from the muscle biopsy.
  • •Aspirin and Non-steroidal anti-inflammatory agents are not exclusions but should be stopped 1 week prior to muscle biopsy (subset of subjects).

研究组 & 干预措施

HIV-uninfected

Active Comparator

HIV-uninfected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.

干预措施: High-intensity cardiovascular and resistance exercise (Other)

HIV-uninfected

Active Comparator

HIV-uninfected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.

干预措施: Moderate-intensity cardiovascular and resistance exercise (Other)

HIV-infected

Experimental

HIV-infected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.

干预措施: High-intensity cardiovascular and resistance exercise (Other)

HIV-infected

Experimental

HIV-infected men and women, age 50-70 years. All participants will exercise at a moderate intensity (cardiovascular + resistance training) for 12 weeks, then will be randomized to continue moderate intensity or advance to high intensity exercise for an additional 12 weeks.

干预措施: Moderate-intensity cardiovascular and resistance exercise (Other)

结局指标

主要结局

Time to Rise From a Chair 10 Times (Modified From the Original Short Physical Performance Battery)

时间窗: 24 weeks

Chair rise time is measured as a continuous variable of time to stand up from a sitting position 10 times. Lower number = faster; larger number = slower

次要结局

  • Changes in Insulin-like Growth Factor (IGF)-1(24 weeks)
  • Changes in Inflammation (Interleukin-6 [IL-6], Soluble Tumor Necrosis Factor Receptors 1 and TNF-alpha.(Baseline and 24 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验